Epitranscriptomic analysis reveals clinical and molecular signatures in glioblastoma
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
This study characterizes the glioblastoma (GB) epitranscriptomic landscape in patient who evolve to progressive disease (PD) or pseudo-progressive disease (psPD). Novel differences in N6-Methyladenosine (m6A) RNA methylation patterns between these groups are identified in the first biopsy. Retrospective data of patients that were eventually deemed to have progressive disease or pseudoprogressive disease was captured from the electronic health record, and RNA from the first resection specimen was utilized to evaluate N6-methyladenosine (m6A) biomarkers from FFPE samples. Molecular analysis of m6A methylation modified RNA employed ACA-based RNase MazF digestion. After Quantitative Normalization with ComBat to mitigate batch effects, we identifed differentially methylated transcripts and gene expression analyses, co-expression networks analyses with WGCNA, and subsequently performed gene set GO and KEGG enrichment analyses. Enrichments for metabolic biological processes and pathways were identified in our differential methylated transcripts and select module eigengene networks highlighted key co-expressed genes intricately tied to distinct phenotypes/traits in patients that would ultimately be deemed PD or psPD. Our study identified key genes and pathways modified by m6A RNA methylation associated with cell metabolism alterations, highlighting the importance of understanding m6A mechanisms leading to the oncometabolite accumulation governing PD versus psPD patients. Furthermore, these data indicate that epitranscriptomal differences between PD versus psPD are detected early in the disease course.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Epitranscriptomic analysis reveals clinical and molecular signatures in glioblastoma
- Date Crossref
- 11/04/2025
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Florida International University Departament of Cellular and Molecular Medicine pays non établi dans la noticeUniversité ou école supérieure
-
The Ohio State University Wexner Medical Center Department of Pathology pays non établi dans la noticeÉtablissement de santé
-
The Ohio State University Center for Biostatistics pays non établi dans la noticeUniversité ou école supérieure
-
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute pays non établi dans la noticeÉtablissement de santé
-
Baptist Health South Florida pays non établi dans la noticeÉtablissement de santé
-
Departament of Neuropathology and Clinical Informatics pays non établi dans la noticeÉtablissement de santé
Departament of Cellular and Molecular Medicine — Florida International University, Department of Pathology — The Ohio State University Wexner Medical Center et Center for Biostatistics — The Ohio State University, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.